Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.63 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | FKBP1A | P62942 | 7/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597880 | 0.96 | TAAR1 (0.61) | TAAR1EPHX1KMT2AALDH1A1FKBP1A | |
| SCHEMBL4821845 | 0.92 | TAAR1 (0.74) | TAAR1EPHX1KMT2AALDH1A1EPHX2 | |
| SCHEMBL4819679 | 0.86 | TAAR1 (0.67) | TAAR1EPHX1KMT2AALDH1A1FKBP1A | |
| SCHEMBL4597877 | 0.83 | TAAR1 (0.65) | TAAR1EPHX1KMT2AALDH1A1FKBP1A | |
| SCHEMBL4598121 | 0.83 | TAAR1 (0.54) | TAAR1EPHX1KMT2AALDH1A1 | |
| SCHEMBL18342995 | 0.81 | EPHX1 (0.63) | TAAR1EPHX1ALDH1A1FKBP1AEPHX2 | |
| SCHEMBL5815460 | 0.80 | EPHX1 (0.66) | TAAR1EPHX1KMT2AALDH1A1FKBP1A | |
| SCHEMBL13743588 | 0.80 | TAAR1 (0.77) | TAAR1EPHX1KMT2AALDH1A1FKBP1A | |
| SCHEMBL4825255 | 0.80 | SMN1; SMN2 (0.52) | TAAR1ALDH1A1EPHX2 | |
| SCHEMBL4598776 | 0.80 | EPHX1 (0.56) | TAAR1EPHX1ALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | claimed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | claimed |
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032484-A1 | Cathepsin K inhibitors | CTSK, CTSS, CTSF | TAAR1 2307/4885EPHX1 3175/4885KMT2A 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.